Drug Type Small molecule drug |
Synonyms M 102 (Aclipse Therapeutics), M102 (Aclipse Therapeutics) |
Target |
Mechanism HSF1 activators(heat shock transcription factor 1 activators), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Aclipse Therapeutics LLCStartup |
Active Organization Aclipse Therapeutics LLCStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyotrophic Lateral Sclerosis | Preclinical | US | Aclipse Therapeutics LLCStartup | 23 Oct 2023 |
Friedreich Ataxia | Preclinical | US | Aclipse Therapeutics LLCStartup | 23 Oct 2023 |
Parkinson Disease | Preclinical | US | Aclipse Therapeutics LLCStartup | 23 Oct 2023 |